Physician profile
Rose Snyder
NPI 1346772118
$2,263.93
in general payments reported to CMS, 2019-2025
35 companies · $65.01 in 2025
The $65.01 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $710 · 2024: $1,489 · 2025: $65.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,117 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,116.95 |
| Education | $146.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $387.28 | 2023-2024 | Tagrisso, Imfinzi, Enhertu |
| Pfizer INC. | $216.61 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $199.44 | 2023-2024 | Iclusig, Fruzaqla, Vpriv |
| Novartis Pharmaceuticals Corporation | $170.44 | 2023-2024 | |
| Lilly USA, LLC | $100.98 | 2023-2024 | Jaypirca, Verzenio, Retevmo |
| Astellas Pharma US INC | $97.85 | 2023-2025 | Xtandi |
| Merck Sharp & Dohme LLC | $83.05 | 2023-2024 | Keytruda, Lynparza, Welireg |
| Array Biopharma INC | $70.38 | 2024 | Braftovi, Mektovi, Lorbrena |
| Genentech USA, INC. | $66.78 | 2024 | Tecentriq, Phesgo, Alecensa |
| Seagen INC. | $64.99 | 2023 | |
| Alexion Pharmaceuticals, INC. | $57.84 | 2024-2025 | Ultomiris |
| Daiichi Sankyo INC. | $56.66 | 2024 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $53.76 | 2023 | Opdivo |
| Myriad Genetic Laboratories, INC. | $49.96 | 2024 | Myrisk |
| Incyte Corporation | $46.50 | 2023-2024 | Jakafi, Monjuvi, Pemazyre |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $40.78 | 2024 | Ojjaara |
| Gilead Sciences, INC. | $39.96 | 2024 | |
| Deciphera Pharmaceuticals INC. | $33.11 | 2024 | Qinlock |
| Aveo Pharmaceuticals, INC. | $31.31 | 2024 | |
| Csl Behring | $30.69 | 2023 | Kcentra |
| Sobi, INC | $30.66 | 2024 | |
| Boston Scientific Corporation | $28.65 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Eisai INC. | $27.71 | 2023 | |
| Menarini Silicon Biosystems, INC. | $27.58 | 2024 | |
| Servier Pharmaceuticals LLC | $26.88 | 2024 | |
| Octapharma USA, INC. | $26.70 | 2023 | Octagam Immune Globulin (Human) |
| Bayer Healthcare Pharmaceuticals INC. | $24.90 | 2024 | |
| Pharmacosmos Therapeutics INC. | $24.36 | 2024 | Cosela |
| Karyopharm Therapeutics INC. | $24.20 | 2024 | Xpovio |
| Sun Pharmaceutical Industries INC. | $23.70 | 2024 | |
| Janssen Biotech, INC. | $22.11 | 2024 | Imbruvica, Darzalex |
| Genzyme Corporation | $22.09 | 2024 | |
| Taiho Oncology, INC. | $21.60 | 2025 | |
| Legend Biotech USA INC. | $19.53 | 2024 | |
| Abbvie INC. | $14.89 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.